Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials

References

• Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018. Issue 5. Art. No.: CD009069.
   PubMed Web of Science ®Google Scholar
• Cochrane Collaboration. Does HPV vaccination prevent the development of cervical cancer? Are there harms associated with being vaccinated? Press Conference; 2018 May 7; London: Cochrane. Available from: https://www.cochrane.org/news/does-hpv-vaccination-prevent-development-cervical-cancer-are-there-harms-associated-being
   Google Scholar
• IARC Monograph Working Group. IARC monographs on the evaluation of carcinogenic risks to humans. vol 90: human Papillomaviruses. Lyon: IARCPress; 2007.
   Google Scholar
• Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsagué X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–2686.
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines - immune responses. Vaccine. 2012;30(Suppl 5):F83–F87.
   PubMed Web of Science ®Google Scholar
• Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301–323.
   PubMedGoogle Scholar
• Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–192.
   PubMed Web of Science ®Google Scholar
• Herbert A, Arbyn M, Bergeron C. Why CIN3 and CIN2 should be distinguished on histological reports. Cytopathology. 2008;19:63–64.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009;27:5612–5619.
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10:2147–2162.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–1651.
   PubMed Web of Science ®Google Scholar
• Konno R, Yoshikawa H, Okutani M, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother. 2014;10:1781–1794.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4–5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow - up from a randomised control trial. Lancet. 2006;367:1247–1255.
   PubMed Web of Science ®Google Scholar
• Sow PS, Watson-Jones D, Kiviat N, et al. Safety and Immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25 year-Old HIV-Seronegative African girls and young women. J Infect Dis. 2013.
   PubMed Web of Science ®Google Scholar
• Zhu F, Li J, Hu Y, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Hum Vaccin Immunother. 2014;10:1795–1806.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer. 2014;135:2612–2622.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18–25 years: event-triggered analysis of a randomized controlled trial. Cancer Med. 2017;6:12–25.
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health. 2010;46:142–151.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human Papillomavirus-16/18 AS04-adjuvanted vaccine and combined Hepatitis A and B vaccine in girls. J Adolesc Health. 2012;50:38–46.
   PubMed Web of Science ®Google Scholar
• Schmeink CE, Bekkers RL, Josefsson A, et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine. 2011;29:9276–9283.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775–786.
   PubMed Web of Science ®Google Scholar
• Ngan HY, Cheung AN, Tam KF, et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J. 2010;16:171–179.
   PubMedGoogle Scholar
• Medina DM, Valencia A, de V A, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health. 2010;46:414–421.
   PubMed Web of Science ®Google Scholar
• Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res. 2010;36:123–132.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim KT, Kim JH, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10–14 years. J Korean Med Sci. 2010;25:1197–1204.
   PubMed Web of Science ®Google Scholar
• Kim SC, Song YS, Kim YT, et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15–25 years old healthy Korean women. J Gynecol Oncol. 2011;22:67–75.
   PubMed Web of Science ®Google Scholar
• Lim BK, Ng KY, Omar J, et al. Immunogenicity and safety of the AS04-adjuvanted Human Papillomavirus-16/18 cervical cancer vaccine in malaysian women aged 18–35 years: a randomized controlled trial. Med J Malaysia. 2014;69:2–8.
   PubMedGoogle Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154–1168.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Ebihara K, Tanaka Y, et al. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine (GARDASIL((R))) in Japanese women aged 18 to 26 years. Cancer Sci. 2013;104:465–472.
   PubMed Web of Science ®Google Scholar
• Kang S, Kim KH, Kim YT, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer. 2008;18:1013–1019.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;1459–1466.
   PubMed Web of Science ®Google Scholar
• Mugo N, Ansah NA, Marino D, et al. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26-áyears of age in Sub-Saharan Africa. Hum Vaccin Immunother. 2015;11:1323–1330.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105:28–37.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Bzhalava D, Guan P, Franceschi S, et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445:224–231.
   PubMed Web of Science ®Google Scholar
• Hartwig S, St Guily JL, Dominiak-Felden G, et al. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer. 2017;12:19.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsagué X, et al. Cervical HPV prevalence in five continents: meta-analysis on one million women with normal cytology. J Infect Dis. 2010;202:1789–1799.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Vanden Broeck D, Benoy I, et al. Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiol. 2016;41:152–158.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17:1293–1302.
   PubMed Web of Science ®Google Scholar
• Pagliusi SR, Teresa AM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23:569–578.
   PubMed Web of Science ®Google Scholar
• WHO. Safety of HPV vaccines (from meeting of 2–3 December, 2015). Weekly Epidem Record. 2016;91:26–28.
   Google Scholar
• Phillips A, Patel C, Pillsbury A, et al. Safety of human Papillomavirus vaccines: an updated review. Drug Saf. 2018;41:329–346.
   PubMed Web of Science ®Google Scholar
• Bonde U, Joergensen JS, Lamont RF, et al. Is HPV vaccination in pregnancy safe? Hum Vaccin Immunother. 2016;12:1960–1964.
   PubMed Web of Science ®Google Scholar